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Abstract
Background: A 12-week, double-blind, parallel, multi-center randomized controlled trial in 316 adult patients with
major depressive disorder (MDD) was conducted to evaluate the effectiveness of pharmacogenetic (PGx) testing for
drug therapy guidance.
Methods: Patients with a CGI-S ≥ 4 and requiring antidepressant medication de novo or changes in their medication
regime were recruited at 18 Spanish public hospitals, genotyped with a commercial PGx panel (Neuropharmagen®),
and randomized to PGx-guided treatment (n = 155) or treatment as usual (TAU, control group, n = 161), using a
computer-generated random list that locked or unlocked psychiatrist access to the results of the PGx panel depending
on group allocation. The primary endpoint was the proportion of patients achieving a sustained response (Patient
Global Impression of Improvement, PGI-I ≤ 2) within the 12-week follow-up. Patients and interviewers collecting the
PGI-I ratings were blinded to group allocation. Between-group differences were evaluated using χ2-test or t-test, as per
data type.
Results: Two hundred eighty patients were available for analysis at the end of the 12-week follow-up (PGx n = 136,
TAU n = 144). A difference in sustained response within the study period (primary outcome) was not observed (38.5%
vs 34.4%, p = 0.4735; OR = 1.19 [95%CI 0.74-1.92]), but the PGx-guided treatment group had a higher responder rate
compared to TAU at 12 weeks (47.8% vs 36.1%, p = 0.0476; OR = 1.62 [95%CI 1.00-2.61]), and this difference
increased after removing subjects in the PGx-guided group when clinicians explicitly reported not to follow the
test recommendations (51.3% vs 36.1%, p = 0.0135; OR = 1.86 [95%CI 1.13-3.05]). Effects were more consistent in
patients with 1–3 failed drug trials. In subjects reporting side effects burden at baseline, odds of achieving a
better tolerability (Frequency, Intensity and Burden of Side Effects Rating Burden subscore ≤2) were higher in the
PGx-guided group than in controls at 6 weeks and maintained at 12 weeks (68.5% vs 51.4%, p = 0.0260; OR = 2.06
[95%CI 1.09-3.89]).
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Conclusions: PGx-guided treatment resulted in significant improvement of MDD patient’s response at 12 weeks,
dependent on the number of previously failed medication trials, but not on sustained response during the study
period. Burden of side effects was also significantly reduced.
Trial registration: European Clinical Trials Database 2013-002228-18, registration date September 16, 2013;
ClinicalTrials.gov NCT02529462, retrospectively registered: August 19, 2015.
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Background
Major depressive disorder (MDD) is a leading cause of
disability worldwide [1]. Actions to reduce the impact of
depression on patients, families and healthcare systems
are thus a public health priority. Despite the growing
number of pharmacological treatments at our disposal,
response and remission rates for antidepressants are not
optimal [2] and psychiatry faces the challenge to improve
utilization of current therapeutic tools. Besides failure with
first- or second-line therapy, disability and economic costs
associated with long-term depression are also linked to
high rates of drug-induced adverse effects [3].
Common genetic variation has been estimated to ex-
plain up to 42% of variance in antidepressant response
[4]; however, genome-wide association studies had been
mostly unsuccessful in identifying individual risk vari-
ants and there are only a few examples on the use of
pharmacogenetic information to guide treatment selec-
tion [5, 6]. The role of individual gene variants in the
metabolism and response to psychotropic medications
has been studied by several independent research groups
and current evidence supports the contribution of cer-
tain genes to drug metabolism, safety or efficacy. Among
them, the most replicated findings include cytochrome
P450 genes (mainly CYP2D6 and CYP2C19) and sero-
tonin genes (SLC6A4, HTR2C, HTR2A) as well as the
ABCB1 transporter gene [7–10]. Recently, the Clinical
Pharmacogenetics Implementation Consortium (CPIC)
has published guidelines for drug selection and/or dos-
ing of tricyclic antidepressants [11] and selective sero-
tonin reuptake inhibitors [12] based on genotypes for
CYP2D6 and CYP2C19. Moreover, pharmacogenomics
information has been incorporated into drug labels both
in the US and EU [13, 14]. Pharmacogenetics-driven
precision medicine based on prediction of therapeutic
efficacy, tolerability and side-effects could help reduce
the time spent until the ‘right drug at the right dose’ is
attained [15]. However, for an adequate clinical implemen-
tation of pharmacogenetic testing in psychiatry, informa-
tion from different genes influencing pharmacokinetic and
pharmacodynamic aspects of drug response must be inte-
grated, as well as practical tools are needed to facilitate
the interpretation of the genotyping results and their
translation into clinical practice [16]. Additionally,
prospective randomized clinical trials (RCT) conducted in
populations of adequate size are necessary to assess the
clinical utility of pharmacogenetic testing in psychiatry. A
recent systematic review reported that a limited number
of studies have shown promise for the clinical utility of
pharmacogenetic testing [17]. However, it was noted that
the majority of studies were not randomized or blinded,
indeed only two small single-center RCT [18, 19] have
been conducted with a proper randomized double-blinded
design. This review also pointed out that published studies
did not assess at what point in the treatment of MDD
pharmacogenetic testing should be utilized.
Neuropharmagen® (NFG®) is a pharmacogenomics-
based precision medicine platform, developed by AB-
Biotics SA (Barcelona, Spain), for managing psychiatric
patients and to assist clinicians in drug selection and/or
dosing choices. Previously, efficacy of pharmacogenetic
testing with this test in the selection of psychiatric medi-
cation was retrospectively evaluated in 182 patients with
various psychiatric diagnoses (depression, anxiety, schizo-
phrenia and bipolar disorder, among others). This study
showed that subjects whose treatment was prescribed fol-
lowing the test recommendations had 3.86-fold greater
odds of improvement than patients whose treatment did
not follow the test recommendations [20]. Also,
stabilization rate at 3-month follow-up was significantly
higher in individuals whose treatment followed the
pharmacogenetic test results.
Here we present the results of a prospective, multicen-
ter, randomized, double-blind clinical trial analyzing the
clinical utility of pharmacogenetic testing with the
Neuropharmagen platform. The aim of the study was to
analyze the efficacy of pharmacogenetic information in
the selection of drug treatments for MDD patients con-
ducted under real-world clinical practice conditions.
Clinical utility of the test is analyzed in terms of im-
provement in depression symptoms and in drug toler-
ability. Additionally, we examined the effect of the
number of previous failed antidepressant trials on the
utility of pharmacogenetic treatment guidance.
Methods
The aim of this prospective, multicenter, randomized,
double-blind, parallel controlled trial was to evaluate the
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effectiveness of pharmacogenetic (PGx) testing for drug
therapy selection in major depressive disorder patients
by comparing clinical outcomes in patients randomized
to PGx-guided treatment or treatment as usual (control
group). This randomized controlled trial adheres to the
CONSORT guidelines [21].
Study sample
Five hundred and twenty patients (both outpatients and
inpatients) were enrolled from 18 hospitals and associ-
ated mental health centers in Spain from July 29, 2014
to June 15, 2015 (Additional file 1: Figure S1) and pro-
vided a saliva sample for DNA analysis. Eligible subjects
were 18 years of age and over, with a principal diagnosis
of major depressive disorder according to the Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV-TR)
criteria. Inclusion criteria were: i) subjects with a clinician-
rated score in the Clinical Global Impression-Severity
(CGI-S) scale ≥4 both at screening and randomization
visit [22]; ii) subjects who, according to the doctors’ as-
sessment, required medication de novo or were receiving
treatment and required substitution or addition of drug
treatment with an antidepressant drug. To obtain a repre-
sentative sample, individuals with secondary comorbid
psychiatric and other medical illness could be included.
Only primary psychiatric diagnoses other than MDD,
pregnant and breastfeeding women, as well as patients re-
quiring treatment with quinidine, cinacalcet and/or terbi-
nafine (known CYP2D6 strong inhibitors) were excluded.
Data collection
Sociodemographic data, clinical diagnosis, duration of
the depressive episode and current and past treatment
for MDD as well as CGI-S scale (both clinician- and
patient-rated) were recorded at the screening visit. Base-
line (randomization visit) and follow-up visits at 6 and
12 weeks were conducted by study investigators on a
single-blinded manner (Fig. 1), whereas blinded inter-
viewers conducted telephone interviews at 4, 8 and
12 weeks to collect the Patient Global Impression of Im-
provement (PGI-I) scale (primary study variable [22] on
a double-blinded manner. During the visits in person,
drug treatments for MDD, changes and reasons for the
changes and/or discontinuation were recorded. Clinical
assessment performed by the treating psychiatrists (i.e.
single-blinded) included the following scales: 17-item
Hamilton Depression Rating Scale (HDRS-17) [23], Fre-
quency, Intensity, and Burden of Side Effects Ratings
(FIBSER) [24], clinician-rated and patient-rated CGI-S
scale, Sheehan Disability Inventory (SDI) [25, 26], and
Treatment Satisfaction with Medicines Questionnaire
(SATMED-Q) [27].
Genotyping and reporting of test results
At the screening visit, all study subjects provided a saliva
sample for DNA extraction and genotyping of the gen-
etic polymorphisms. DNA was extracted from patient
saliva samples with the Genomic DNA Isolation Kit
(Norgen Biotek Corp., Thorold, ON, Canada) following
the manufacturer’s instructions. Genotyping of single
nucleotide polymorphisms was performed by OpenArray®
Technology on the QuantStudio™ 12 K Flex Real-Time
PCR System (Thermo Fisher Scientific Inc., Waltham,
MA USA) using a custom designed array (see Additional
file 1: Table S1 for the list of polymorphisms analyzed).
CYP2D6 copy number analysis was performed in an
Applied Biosystems® 7500 Real-Time PCR System using
Hs04083572_cn and Hs04502391_cn TaqMan copy num-
ber assays targeting CYP2D6 intron 2 and intron 6, re-
spectively, and RNase P copy number assay as a reference
(Thermo Fisher Scientific Inc., Waltham, MA USA).
The Neuropharmagen pharmacogenetic report (AB-
Biotics SA, Barcelona, Spain) was accessible through a
web-based computer-aided system (Additional file 1:
Figure S2), provided information for 50 drugs (antide-
pressants, antipsychotics, mood stabilizers and other
CNS drugs) and integrated three elements: (a) pharma-
cogenomic data derived from the analysis of genetic
polymorphisms in 30 genes associated with drug effi-
cacy, metabolism or specific adverse effects (Additional
file 1: Table S1); (b) information on pharmacological in-
teractions, involving psychotropic drugs as well as con-
comitant medications; and (c) data on specific clinical
conditions and lifestyle influences. For each drug, the
pharmacogenomics interpretative report (Additional file 1:
Figure S3) highlights gene-drug interactions and provides
drug-specific treatment recommendations as per FDA-
approved drug labeling [13], published pharmacogenetic
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Fig. 1 Schematic of the AB-GEN study procedures. TC: telephone controls; V: follow-up visits; DB: double-blind evaluation; SB: single-blind evaluation
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guidelines [11, 12, 28] and selected clinical studies
[29–35]. For example, in a patient carrying the CYP2D6*4/
*4 diplotype (predicted as a poor metabolizer phenotype),
the antidepressant amitriptyline will be highlighted in yel-
low and the following recommendation will be associated
to the drug: “Consider an alternative drug not metabolized
by this pathway. If this drug is warranted, consider a 50%
reduction of the recommended starting dose. Use thera-
peutic drug monitoring to guide dose adjustments”. More-
over, using a comprehensive built-in database of drug-drug,
drug-clinical condition and drug-lifestyle factor interactions
based on FDA-approved drug labeling, the web platform
displays the most relevant alerts. The reporting algorithm
prioritizes alerts using a color-coding system indicating
with a red label alerts associated with adverse effects, with a
yellow label alerts associated with drug metabolism varia-
tions, and with a green label alerts associated with increased
likelihood of positive response. Whenever two or more
alerts of different category are present for a particular drug,
the summary table of the report highlights the most im-
portant alert whereas the detailed drug information section
displays all the identified.
Randomization, concealment and study groups
Subjects fulfilling all inclusion criteria and none of the
exclusion criteria were included in the study and ran-
domized to either the PGx-guided group or the control
group (treatment as usual, TAU). Randomization was
stratified by centre with a 1:1 ratio for intervention and
control group, using a computer-generated random list.
Patient blinding was ensured through a computer-
assisted system: for each patient randomized to the
PGx-guided group, the system provided the treating psy-
chiatrists a numerical code to unlock their online access
to the individual patient’s pharmacogenetics test report.
At their discretion, treating psychiatrists could also
check drug-drug, drug-clinical condition and drug-
lifestyle factor interaction alerts in the reports online
platform for patients in the PGx-guided group. For pa-
tients in the control group, clinicians did not have access
to their reports until the end of the study and subjects
were treated as usual without pharmacogenetic informa-
tion. Patients in both study groups were treated by the
same psychiatrists, who could choose whichever drug,
drug combination and dosing schedule suited the best to
each patient. For patients in the PGx-guided group,
treating psychiatrists were asked to indicate whether, in
their own judgment, the medication they prescribed was
in accordance to the results provided by the test or not.
As the treating psychiatrists were not blinded regarding
patient allocation, assessment of the primary variable
(PGI-I) was conducted by independent telephone inter-
viewers who were blinded regarding patient allocation,
thus ensuring a double-blind evaluation.
Statistical analysis
The primary outcome of the study was the efficacy of
the pharmacogenetic information in the selection of
drug treatments for MDD considering the proportion of
patients achieving a sustained response through a 12-
week follow up period. A response was considered when
the patient had a PGI-I score of 2 or less at a given
phone interview (i.e. reported their condition was “Much
better” or “Very much better”). A sustained response
was achieved when a patient was classified as a re-
sponder on at least two consecutive evaluations, and
maintained that status until the final visit of the study.
The PGI-I scale was selected as the primary study vari-
able as it allowed double-blinded evaluation of patient-
rated improvement through phone interviews, and could
be easily incorporated into interviews at 4, 8 and
12 weeks. Sample size was calculated to detect a signifi-
cant difference with a sustained response around 30% in
the control group and of 45% in the study group with
alpha = 0.05 and power = 80%, resulting in a target N of
390 (195 per group) when assuming a 20% loss to
follow-up. Adding an expected loss of 25% of patients
between screening visit and randomization visit due to
improvement of their condition or not requiring medica-
tion changes resulted in the total target N of 520. A per
protocol population was defined by excluding subjects
randomized to the PGx-guided group when their treat-
ing psychiatrists explicitly reported to have prescribed a
treatment regime not in accordance to the test results.
Secondary variables were response at the end of the 12-
week follow-up (based on a PGI-I score of 2 or less),
clinical progression (based on HDRS-17 score), severity
of the disorder (based on the CGI-S score), tolerability
of treatment (based on the FIBSER score), patient satis-
faction with treatment (according to the SATMED-Q
score), and patient disability (based on the SDI score).
Regarding treatment tolerability, the cutoff for the ac-
ceptability of side effects was established at a FIBSER
Burden subscore equal lower than 2, following the built-
in recommendations in the FIBSER questionnaire. A de-
scriptive statistics analysis for all variables was per-
formed. χ2 tests or Student’s t-tests were used to
compare pairwise differences between groups and be-
tween baseline and follow-up visits as per data type,
while Pearson’s r was used to measure correlation be-
tween variables. Shapiro-Wilk test was used to verify
normality of data. All reported p-values are raw p-values.
Because 4 outcomes comparing the PGx-guided group
to the control one were calculated on the primary vari-
able (sustained response and response on week 12, full
population and per-protocol population), a p-value
threshold corrected for multiple comparisons was calcu-
lated. A key assumption of multiplicity correction methods
such as Bonferroni or Sidak is the independence of the
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assessed outcomes. Thus, because of the existing cor-
relation among the outcomes calculated on the primary
variable, a correlation-corrected method was used [36],
resulting in an adjusted p-value threshold of 0.0271
when considering the lowest correlation observed
between these 4 variables (i.e. the more conservative
correction). The effect of time on response rate within
each study group was assessed using the Cochran-
Armitage modification of the χ2 tests (to account for
the order of visits). Effect sizes on the HDRS-17 scale
as a function of the number of previously failed anti-
depressant therapies for the current episode were calcu-
lated using Hedge’s formula for Cohen’s d [37]. Post-hoc
sub-analyses were performed in subjects having failed 1
to 3 previous medications. Statistical analyses were per-
formed using SAS version 9.3 software (SAS Institute
Inc., Cary, NC, USA).
Results
Sociodemographic and clinical information at baseline is
shown in Table 1 and patient flow through the study is
summarized in Additional file 1: Figure S4. Of the 520
patients with a diagnosis of MDD enrolled in the study,
316 fulfilled inclusion criteria and were randomized
(intent-to-treat population). Evaluated subjects had a
mean age of 51.2 years (± 12.6), 63.6% were women
and 92.4% Caucasian, and had a mean duration of
MDD since diagnosis of the current depressive episode
of 60.2 months (± 94.4), and a median of 14.1 months.
At randomization, the mean HDRS-17 score was 19.2
(± 5.8). The main psychiatric comorbidities were anxiety
disorder (35.8%) and substance abuse disorders (12.6%),
and most patients were not drug-naïve (84.2%), with an
average of 2.6 (± 2.2) previous antidepressant medication
trials for the current episode, varying from 0 to 15. Similar
scores were recorded at baseline in both the study and
control groups in all questionnaires, except for the Inten-
sity and Burden of side effects items of the FIBSER scale,
which were significantly higher in the study group (Addi-
tional file 1: Table S2). The proportion of subjects not at-
tending visits in the study and control groups was 7.1% vs
11.2%, respectively, while the proportion of subjects not
answering telephone interviews for the primary variable
was 12.3% vs 10.6%, respectively. Thus, there were no sta-
tistically significant differences in patient drop-outs (sub-
jects not attending visits) nor in loss to follow-up for the
primary variable (subjects not answering the telephone
interviews).
Clinical efficacy on depression outcomes
The PGI-I score was evaluated in a double-blinded man-
ner at 4, 8 and 12 weeks. Differences in sustained re-
sponse starting at 4 or 8 weeks could not be observed in
this study (Fig. 2a). The number of responders at the
end of the study (i.e. indicating their condition was
“Much better” or “Very much better” on week 12) was
Table 1 Demographic and clinical characteristics of the study population
Study group Control group p-value
Subjects 155 161
Age (years), mean (SD) 51.74 (12.05) 50.74 (13.12) 0.4801
Gender, n (%) Female 99 (63.9) 102 (63.4) 0.9239
Male 56 (36.1) 59 (36.6)
Ethnicity (%) Caucasian 145 (93.5) 147 (91.3) 0.6215
Latin American 7 (4.5) 10 (6.2)
Other 3 (2.0) 4 (2.5)
Time since diagnosis (months), mean (SD) 58.89 (93.29) 61.52 (95.80) 0.8050
Main diagnosis, n (%) Major depression 146 (94.2) 148 (91.9) 0.7035
Dysthymic disorder 5 (3.2) 8 (5.0)
Other non-specified depressive
disorder
4 (2.6) 5 (3.1)
Clinical Global Impression-Severity (CGI-S) scale,
clinician-rated, mean (SD)
4.50 (0.62) 4.40 (0.57) 0.1663
Hamilton Depression Rating Scale (HDRS-17), mean (SD) 19.47 (5.96) 19.01 (5.71) 0.4818
Patient Global Impression of Improvement scale (PGI-I),
single-blinded inclusion criterion, n (%)
No change 108 (69.7) 123 (76.4) 0.4026
A little worse 26 (16.8) 20 (12.4)
Much worse 16 (10.3) 16 (9.9)
Very much worse 5 (3.2) 2 (1.2)
Previous failed psychiatric medication trials, mean (SD) 2.55 (2.35) 2.57 (2.10) 0.9175
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nominally higher in the PGx-guided group than in the
control group (47.8% vs 36.1%, p = 0.0476, OR = 1.62
[95%CI 1.00-2.61]). Moreover, in a within group analysis,
the response rate in the PGx-guided group increased
progressively in the three phone interviews from week 4
to week 12 (p = 0.0009), while the increase within the
control group was not statistically significant (Fig. 2b).
In 17 of the subjects of the PGx-guided group, the
treating psychiatrists reported to have prescribed medi-
cations in disagreement with the test results during the
study period. Thus, the per-protocol analysis excluded
these subjects from the PGx-guided group. Again, a sig-
nificant difference in sustained response was not ob-
served in this analysis, but the difference in the response
TC1 (4 weeks) TC2 (8 weeks) TC3 (12 weeks) 
Study 28.47% 40.56% 47.79% 
Control 31.97% 37.41% 36.11% 
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Fig. 2 a Sustained response rate (PGI-I score ≤ 2 on two consecutive evaluations by phone interview). b Response rate based on subjects
reporting a PGI-I score ≤ 2 and c change in HDRS-17 score in the total ITT population. TC: telephone controls; #p < 0.1; *p < 0.05
Pérez et al. BMC Psychiatry  (2017) 17:250 Page 6 of 13
rate at 12 weeks between the PGx-guided group and
controls increased (51.3% vs 36.1%, p = 0.0135, OR = 1.86
[95%CI 1.13-3.05]). When correcting for multiplicity of
analysis for the 4 comparisons of PGI-I between the
PGx-guided and the control group (sustained response
and response at 12 weeks, full population and per-
protocol population), this p-value of 0.0135 is below the
correlation-adjusted threshold calculated of 0.0271 (see
Methods). Besides, response rate at 12 weeks among the
17 subjects excluded in the per-protocol analysis was
very low (23.5%, p = 0.0323, compared to the remaining
subjects of the PGx-guided group).
In the secondary analyses, improvement in depression
rating scores was also statistically significant for the 17-
item Hamilton Depression Rating Scale (HDRS-17) at
6 weeks (p = 0.0364) and a trend at 12 weeks (p = 0.0771)
(Fig. 2c). Patients in the PGx-guided group presented a
higher reduction in HDRS-17 (approximately a point and
a half difference) than TAU control patients, that corre-
sponded to Cohen’s d values of 0.25 and 0.21 at 6 and
12 weeks, respectively. Moreover, significant results favor-
ing the PGx-guided treatment group were found in
clinician-rated CGI-S, all three FIBSER indices and
SATMED-Q total and partial scores, as well as the SDI
Perceived Social Support partial score, but not in patients-
rated CGI-S (Additional file 1: Table S3). Response and
remission rates calculated post-hoc on the HDRS-17
(single-blinded) are reported in Additional file 1: Table S4,
and baseline severity, as determined by HDRS-17, was
found to impact the difference in response rate between
PGx-guided and control groups. No significant differences
were found in the distribution of antidepressants types
prescribed in the PGx-guided and the control groups
(Additional file 1: Table S5). Of note, PGI-I rating on week
12 was significantly correlated to change from baseline in
both the clinician-rated CGI-S and HDRS-17 (r = −0.46
and r = −0.30, respectively, p < 0.0001 in both cases), indi-
cating that the lower the PGI-I score (i.e. more improve-
ment), the larger the reduction in CGI-S and HDRS
scores. Also, PGI-I rating on week 12 was significantly
correlated to sustained response (r = 0.56, p < 0.0001).
Because the PGx web platform also provides a tool to
assess the impact of drug-drug, drug-clinical condition
and drug-lifestyle factor interactions, the PGx sample
was further split in two groups depending on whether
the treating physicians had consulted the interactions
tool. Responder rate was slightly higher in the group
where interaction alerts had been consulted, compared
to use of PGx alone (50.0% vs 45.8%), but the difference
was not significant. Conversely, an opposite trend was
observed in HDRS-17 score, as the reduction was
slightly larger in the group using PGx information alone,
both on week 6 and 12, but again the difference was not
statistically significant.
Due to the large heterogeneity observed in the number
of previous antidepressant medication trials for the
current depressive episode, a sub-analysis was performed
to evaluate the effect of this variable on the benefit of
pharmacogenetic testing, by means of calculation of
Cohen’s d. Study subjects with 1, 2 or 3 previous failed
treatments for the current episode had a small clinical
benefit compared to actively treated controls as seen by
Cohen’s d calculated from the change in HDRS-17,
whereas drug naïve subjects and those having received 4
or more medication trials did not (Additional file 1:
Table S6). Among subjects having received 1 to 3 previous
psychiatric treatments (n = 173), statistically significant
differences were identified at 12 weeks in the percentage
of patients with a positive response to treatment based on
the PGI-I score (51.8% vs 31%, p = 0.0058, OR = 2.39
[95%CI 1.28-4.44]), and on the HDRS-17 score both at
6 weeks (p = 0.0237) and 12 weeks (p = 0.0083) (Fig. 3a
and b). At 12 weeks, the mean and median reductions in
HDRS-17 were 3 points larger in the study group than in
the control group (Additional file 1: Table S7), resulting in
a Cohen’s d value of 0.41.
Medication tolerability
To assess the impact of pharmacogenetic testing on
medication tolerability, subjects with a FIBSER Burden
subscore of ≥1 at baseline were analyzed (n = 177). At
baseline, this tolerability subpopulation did not display
significant differences among groups in the FIBSER
Burden domain score (Additional file 1: Table S8). Not-
ably, the likelihood of reaching a FIBSER Burden
score ≤ 2 (i.e. no general need to address side effects)
was significantly higher in the PGx-guided treatment
group after 6 weeks (66.7% vs 50.0%, p = 0.0294,
OR = 2.00 [95%CI: 1.07 – 3.75]), and was maintained at
12 weeks (68.5% vs. 51.4%, p = 0.0260, OR = 2.06
[95%CI: 1.09 – 3.89]) (Fig. 4). To assess the independ-
ence between changes in depression symptoms and side
effect burden, Pearson correlation was measured be-
tween the change in the FIBSER Burden subscore at 6
and 12 weeks and the change in HDRS-17 score on the
same visits. Although the effect was statistically signifi-
cant in both visits (p = 0.003 and p = 0.023), the effect
sizes were very small (r = 0.18 and r = 0.14, respectively),
suggesting that the improvement in medication toler-
ability made a significant but small effect on the im-
provement in the HDRS-17 scale.
Discussion
To our knowledge this is the first large-scale multicenter,
prospective, double-blind randomized clinical trial (RCT)
to assess whether PGx-guided selection of treatment is
more effective than unguided treatment in improving
MDD patients’ response and poor drug tolerability. Our
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results show that achievement of sustained response
within the 12-week follow-up period (primary outcome of
the study) did not differ between the two groups. Positive
results were found within 12 weeks of treatment based on
the double-blind evaluation of patient-rated improvement
(PGI-I), especially when the 17 subjects randomized to the
PGx-guided group but being prescribed a drug regime not
in accordance with the test results were excluded. Positive
results were also observed within the first 6 weeks of treat-
ment according to HDRS-17 change (single-blind).
Proper randomization and blinding are necessary be-
cause performing a genetic test has the potential to
affect the attitude of the patient towards the post-test
medication, resulting in increased adherence, as has
been recently shown for other medical conditions [38].
In our study, we ensured double-blinding by using the
patient rating of improvement (PGI-I scale), collected by
blinded phone interviews, as the primary variable. The
treating psychiatrists, which selected the drug regiment
for patients either in the PGx-guided or TAU groups,
could not be blinded and therefore phone interviews by
independent raters were considered as the best option to
guarantee double-blinded assessments. The present
study has been conducted with conditions representative
of real-world clinical practice. Most subjects enrolled
were not drug-naïve (having received up to 15 previous
courses of different psychiatric medication for the
current depressive episode), and a substantial percentage
of them displayed concurrent psychiatric disorders such
as anxiety and substance abuse, while 17.8% displayed a
depression of mild severity. In contrast, Phase III clinical
trials of antidepressant efficacy commonly tend to employ
more stringent inclusion/exclusion criteria, typically ex-
cluding subjects with comorbidities, those with HDRS-17
baseline severity of <19 and those with a current episode
lasting more than 24 months [39]. In this regard, efficacy
of antidepressant medication compared with placebo in-
creases with severity of the disorder and tends to be
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smaller in patients with mild to moderate depression [39,
40]. In our study, comorbidities were not excluded and pa-
tients were selected according to a CGI-S score ≥ 4, which
may explain the finding of a 17.8% of subjects with
HDRS-17 score below 14 at randomization (baseline), the
depression severity cutoff used in the STAR-D study [41].
Furthermore, our study included patients who had failed
multiple previous treatments (65% of the population could
be regarded as refractory).
A recent systematic review indicated that, up until
now, only a handful of studies have examined the effects
of combinatorial pharmacogenomics testing on clinical
outcomes of adult MDD patients [17]. Of these, only
two were randomized clinical trials, and none were
multi-centric studies. In the first one, Winner and col-
leagues found a statistical trend for better outcomes in a
trial conducted in 51 study subjects (26 pharmacogenetic-
guided versus 25 unguided) with baseline HDRS-17 scores
≥14 [18]. Conversely, Singh [19] used a pharmacogenetic
report to adjust drug dosages in 148 MDD patients (74
guided versus 74 unguided) and showed patients in the
guided group had a 2.52-fold increased likelihood of re-
mission. Of note, the latter included subjects with HDRS-
17 scores over 18 only, and excluded smokers, patients
with psychiatric comorbidities, and those receiving known
inducers/inhibitors of CYP2C19, CYP2D6 and ABCB1.
Although with promising results, both studies were con-
ducted in populations of patients of modest size and thus
additional data was needed to firmly establish the utility of
pharmacogenetic testing for the treatment of MDD.
Therefore, regardless of the high heterogeneity of the
AB-GEN full study population in terms of depression se-
verity, length of diagnosis and comorbidities, statistically
significant differences were observed in the PGx-guided
treatment group versus the unguided group, although ef-
fect sizes were modest. The definition of sustained re-
sponse in this study required at least obtaining significant
differences already at 8 weeks, which may be too short a
follow-up period, especially in a design seeking to demon-
strate superiority against treatment as usual (opposed to
trials intending to prove non-inferiority). The statistically
significant increase in response rate in the PGx-guided
group during the study period and the difference observed
against the control group at 12 weeks raise the question
of whether a longer follow-up time could confirm a dif-
ference in sustained response.
The effects of PGx-guided treatment on response
(PGI-I) and HDRS-17 change were more consistent and
clinically relevant in subjects with 1 to 3 unsuccessful
previous drug trials, where a 2.39-fold increase in the
odds of response was found. Hence, our results suggest
that use of pharmacogenetic information to guide treat-
ment adjustments would be justified if the traditional
first line of treatment fails. Our results are in agreement
with previous studies reporting that pharmacogenetic
tools are effective in patients that failed a previous medi-
cation trial [18, 19, 42]. Moreover, the results of this
study are consistent with previous data from a retro-
spective naturalistic study also conducted with Neuro-
pharmagen [20]. However, our results also indicate that
pharmacogenetics tools may be of little benefit to those
patients with large numbers of unsuccessful medication
attempts. We hypothesize this could be due to those pa-
tients having less untested therapeutic alternatives
remaining, and thus the reduction in uncertainty caused
by the test would be smaller. Future studies should at-
tempt to assess this hypothesis.
Remarkably, the present study is also the first pro-
spective multicenter double-blind RCT indicating that
the use of a pharmacogenetic test report improves medi-
cation tolerability as suggested by a statistically significant
reduction in the burden of side-effects. Non-adherence is
a global challenge for psychiatry and has been linked to
poorer outcomes, while improved tolerability facilitates
long-term adherence. In the present study, a very small
correlation was found between the change in HDRS-17
and the change in side effect burden on the same visits,
suggesting that the improved tolerability is not the cause
of the improvement in depression severity during the 12-
week follow-up period.
The pharmacogenetic tool used in this study also al-
lows physicians to check for potential drug-drug, drug-
medical condition and drug-lifestyle factor interactions.
Therefore, we compared those patients whose treating
psychiatrists had consulted for interaction alerts to those
whose treating psychiatrist had not, within the PGx
group. A slight increase in response rate was observed
in the former group, yet the opposite trend was observed
regarding the reduction in HDRS-17, the differences be-
ing not significant in either case. Also, it must be noted
that the number of subjects displaying real interactions
was not determined, and could differ between the two
subgroups, thus compromising their comparability. There-
fore, no conclusions could be drawn regarding whether
the addition of interaction alerts to pharmacogenetic in-
formation had a significant impact.
Personalization of psychiatric treatments using phar-
macogenetic information is emerging as a valuable tool
to identify in advance which medications will be more
effective, which will require dose adjustments or which
may cause meaningful adverse reactions. Besides a
clinically-demonstrated effect on efficacy and tolerability,
for pharmacogenetic data to represent a real benefit for
psychiatric patients it needs to be seamlessly integrated
into clinical practice. Drug response and tolerability pro-
files depend on the combined effects of different genes
as well as environmental and clinical factors. In this re-
gard, the translation of the combined effect of different
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genes into actionable recommendations has been previ-
ously shown to outperform the effect of single genes [43].
The Neuropharmagen web-based platform uses a propri-
etary combinatorial approach to translate pharmacogenetic
as well as pharmacological information into clinical action-
able recommendations. In the case of drug-metabolizing
enzymes polymorphisms, international guidelines (Clinical
Pharmacogenetics Implementation Consortium genotype-
driven dose adjustments, FDA-approved drug labelling) are
included in the recommendations when available.
A number of barriers have been noted for the wide-
spread adoption of precision medicine, such as insuffi-
cient evidence generation, data sharing and slow uptake
of genomic information into clinical care [44]. In this re-
gard, a multi-centric, double-blinded RCT design such
as the one used in our study represents the gold standard
for evidence generation, while having performed the study
in a naturalistic scenario allows to account for the limita-
tions in sharing and uptaking of pharmacogenetic data in
a real-life scenario.
Conclusions
The AB-GEN study contributes to demonstrate that the
use of a pharmacogenetic-based precision medicine plat-
form may have a significant impact on clinical improve-
ment of MDD patients and reduction of drug side effects
compared to standard of care, even if results in sustained
response rates before the end of the 12-week follow-up
were similar in the studied groups. The effect was espe-
cially relevant in subjects with one to three previous failed
antidepressant trials, but not in drug-naïve patients or
those with more than 3 failed drug trials. This study does
have several limitations. Firstly, personnel of AB-Biotics
(developer of Neuropharmagen®) collaborated in the ana-
lysis of the results, the interpretation of the study and the
preparation of the manuscript. Secondly, the clear
majority of participating patients were of Caucasian origin.
Thus, application of findings to other ethnic groups
should be considered with care. Additionally, we acknow-
ledge the limitations of using a simple scale, such as PGI-
I, as the primary outcome assessment. Moreover, epigen-
etic factors are not included in current pharmacogenomic
testing algorithms and thus were not considered in this
study. Future approaches analyzing genetic as well as epi-
genetic factors may increase the predictive capability of
such tools. Also, because most subjects were already on
treatment at study entry and some were under polyther-
apy, we could not clearly establish whether medication
changes occurring during the study affected drugs pre-
scribed in the randomization visit, drugs prescribed before
the randomization visit and kept at the same dose, or pre-
scribed before the randomization visit but whose dosing
had been changed according to the tests results. However,
PGx testing may report several therapeutic alternatives or
complementary drug options for a given patient, and thus
changes in medication after randomization visit in a nat-
uralistic setting cannot be directly related to a success or
failure of a PGx test to deliver useful information. This
further highlights the importance of large, randomized,
multi-centric studies to assess the overall practical effect
of using vs not using PGx information. Finally, additional
studies will be needed for independent replication as well
as to confirm these findings in other psychiatry diagnoses
such as bipolar disorder or schizophrenia.
In summary, the present study found that PGx-guided
prescription has potential to help improve both efficacy
and tolerability compared to treatment as usual in a
naturalistic setting, but such clinical utility likely de-
pends on the patient profile, and should be replicated in
studies with different ethnicities.
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